Correct instructions and precautions for taking Lenvatinib

Lenvatinib (also known as Lenvatinib) is an oral multi-target tyrosine kinase inhibitor commonly used to treat a variety of solid tumors such as thyroid cancer, hepatocellular carcinoma and renal cell carcinoma. This medicine should be taken orally once a day on time. It is recommended to take it at a fixed time every day. It can be taken on an empty stomach or with food. However, try to avoid taking it with high-fat food at the same time to avoid affecting absorption. The capsules should be swallowed whole and should not be chewed, broken or ground to avoid affecting the efficacy of the medicine.

The starting dose of lenvatinib needs to be determined based on the specific indication and patient weight. For example, when treating hepatocellular carcinoma, patients weighing ≥60kg are recommended 12mg/day, <60kg is 8mg/day; when treating differentiated thyroid cancer, the generally recommended starting dose is 24mg/day. If a patient encounters obvious adverse reactions during medication, the doctor can reduce the dosage or discontinue medication according to the specific situation. Do not adjust the dosage on your own.

While taking lenvatinib, blood pressure, liver and kidney function, electrolytes, proteinuria, etc. need to be monitored regularly. This drug may cause adverse reactions such as hypertension, abnormal liver function, and proteinuria. Therefore, close follow-up should be maintained during the initial period of medication and during treatment. Once serious discomfort occurs, such as obvious fatigue, diarrhea, weight loss, hand-foot syndrome, etc., you should communicate with your doctor in time to determine whether the medication regimen needs to be adjusted.

While using lenvatinib, you should avoid taking drugs that may cause drug interactions, such as certain antifungals, antiviral drugs, and antiepileptic drugs. Female patients should use effective contraception during treatment and avoid pregnancy for at least two weeks after stopping the medication. Additionally, patients should avoid ingesting grapefruit or its products as this may interfere with drug metabolism. For patients with significantly impaired liver and kidney function or who are at risk of bleeding, they should be strictly evaluated under the guidance of a doctor before deciding whether to use this drug.

Reference materials:https://www.drugs.com/